Get the Daily Brief
Latest Biotech News
Proteomics International posts sevenfold Q3 revenue after UWA collaboration
Australian diagnostics firm Proteomics International reported A$1.9 million in Q3 2025 revenue, a more than sevenfold increase year‑over‑year driven by a nonrecurring A$1.7 million collaboration...
AI meets multimodal biomolecules and biomarkers — BoltzGen and Guardant‑Zephyr tie ups
Two AI‑driven advances signaled fast adoption of machine learning across discovery and translational pipelines. An MIT team released BoltzGen, an open‑licensed generative model that designs...
Novartis shells out $12B for Avidity—gains three late‑stage RNA drugs
Novartis agreed to acquire Avidity Biosciences for roughly $12 billion, adding three late‑stage antibody‑oligonucleotide conjugate (AOC) programs targeted at neuromuscular diseases. The deal...
Intellia halts nex‑z Phase III dosing after serious liver event
Intellia Therapeutics paused enrollment and dosing in two phase III trials of its CRISPR candidate nex‑z (nexiguran ziclumeran) after a study volunteer was hospitalized with severe liver toxicity....
BridgeBio posts pivotal win — pivots filing plans for rare muscular dystrophy
BridgeBio reported positive Phase III interim results for BBP‑418 in limb‑girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), prompting company plans to meet the FDA to discuss regulatory filing...
Zenas’ obexelimab wipes out MRI lesions — midstage multiple sclerosis win
Zenas Biopharma reported that obexelimab produced a 95% reduction in new gadolinium‑enhancing MRI lesions at Weeks 8–12 in its midstage MoonStone relapsing multiple sclerosis study. The...
Hemab raises $157M to tackle underserved coagulation disorders
Hemab Therapeutics closed a $157 million financing to advance a pipeline focused on rare bleeding disorders, funding pivotal plans and clinical expansion. The Series C round was led by Sofinnova...
USP issues GLP‑1 standards as patient response and counterfeit risks rise
The U.S. Pharmacopeia released reference standards and analytical reference materials to help manufacturers and labs ensure purity and detect impurities in GLP‑1 peptide therapeutics amid surging...
Health Canada clears lecanemab for early Alzheimer’s — conditional authorization
Health Canada issued a Notice of Compliance with Conditions for Eisai and Biogen’s lecanemab (LEQEMBI) to treat adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease...
Neumora advances NLRP3 obesity program after competitor setbacks
Neumora Therapeutics is pressing forward with an NLRP3 inhibitor program for obesity after competitors failed to deliver weight‑loss efficacy. Preclinical data released by the company show that...
Implantable CMOS imager records single‑neuron activity deep in brain
Researchers unveiled an implantable complementary metal–oxide–semiconductor (CMOS) fluorescence imager that achieves single‑neuron resolution deep within brain tissue. The device integrates...
MARTi brings real‑time nanopore metagenomics to field surveillance
Researchers at the Earlham Institute released MARTi, an open‑source software suite that performs real‑time analysis and visualization of nanopore metagenomic data for pathogen detection,...
Novartis bets $12B on RNA delivery: Avidity deal expands neuromuscular pipeline
Novartis announced it will acquire Avidity Biosciences for roughly $12 billion, purchasing a late-stage pipeline built on antibody-oligonucleotide conjugates (AOCs) designed to deliver RNA to...
CRISPR safety alarm: Intellia halts two late‑stage trials after liver toxicity
Intellia Therapeutics paused enrollment and dosing in two phase 3 trials of its in vivo CRISPR candidate after a participant was hospitalized with severe liver injury. The company halted screening...
Zenas posts striking mid‑stage MS signal: Obexelimab slashes new lesions
Zenas Biopharma reported mid‑stage data showing its bifunctional antibody obexelimab cut new gadolinium‑enhancing brain lesions by 95% over 12 weeks in relapsing multiple sclerosis in the...
BridgeBio advances toward approval after Phase III win — FDA meeting planned
BridgeBio reported positive Phase 3 interim results for its limb‑girdle muscular dystrophy candidate, showing statistically significant improvements on a muscle‑stability biomarker and functional...
Leqembi cleared in Canada: Eisai and Biogen land conditional approval
Health Canada issued a Notice of Compliance with Conditions for Eisai/Biogen’s lecanemab (LEQEMBI) for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who are...
Bayer wins FDA OK for non‑hormonal menopause pill — Market competition heats up
The FDA approved Bayer’s Lynkuet, a once‑daily non‑hormonal treatment targeting NK1 and NK3 receptors to reduce moderate‑to‑severe vasomotor symptoms of menopause. Approval was supported by three...
Hemab raises $157M to tackle rare coagulation disorders — Late‑stage trials ahead
Hemab Therapeutics closed a $157 million financing to advance a portfolio aimed at underserved bleeding disorders, including two programs already in clinical testing. The round, led by Sofinnova...
Guardant joins Zephyr AI to speed genomic biomarker discovery
Guardant Health struck a partnership with Zephyr AI to combine Guardant’s multimodal molecular data from its oncology test platform with Zephyr’s analytics to accelerate discovery of genomic...